These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 28646732)

  • 21. Functional outcomes from a head-to-head, randomized, double-blind trial of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder and an inadequate response to methylphenidate.
    Nagy P; Häge A; Coghill DR; Caballero B; Adeyi B; Anderson CS; Sikirica V; Cardo E
    Eur Child Adolesc Psychiatry; 2016 Feb; 25(2):141-9. PubMed ID: 25999292
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Do Treatments for Adult ADHD Improve Emotional Behavior? A Systematic Review and Analysis.
    Surman CBH; Walsh DM
    J Atten Disord; 2022 Dec; 26(14):1822-1832. PubMed ID: 35822610
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine.
    Roskell NS; Setyawan J; Zimovetz EA; Hodgkins P
    Curr Med Res Opin; 2014 Aug; 30(8):1673-85. PubMed ID: 24627974
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systematic review and meta-analysis of pharmacological treatment of the symptoms of attention-deficit/hyperactivity disorder in children with pervasive developmental disorders.
    Reichow B; Volkmar FR; Bloch MH
    J Autism Dev Disord; 2013 Oct; 43(10):2435-41. PubMed ID: 23468071
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discontinuation of pharmacological treatment of children and adolescents with attention deficit hyperactivity disorder: meta-analysis of 63 studies enrolling 11,788 patients.
    Riera M; Castells X; Tobias A; Cunill R; Blanco L; Capellà D
    Psychopharmacology (Berl); 2017 Sep; 234(17):2657-2671. PubMed ID: 28631099
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative efficacy and tolerability of pharmacological interventions for attention-deficit/hyperactivity disorder in children, adolescents and adults: protocol for a systematic review and network meta-analysis.
    Cortese S; Adamo N; Mohr-Jensen C; Hayes AJ; Bhatti S; Carucci S; Del Giovane C; Atkinson LZ; Banaschewski T; Simonoff E; Zuddas A; Barbui C; Purgato M; Steinhausen HC; Shokraneh F; Xia J; Cipriani A; Coghill D;
    BMJ Open; 2017 Jan; 7(1):e013967. PubMed ID: 28073796
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Atomoxetine for attention deficit hyperactivity disorder in children and adolescents with autism: A systematic review and meta-analysis.
    Patra S; Nebhinani N; Viswanathan A; Kirubakaran R
    Autism Res; 2019 Apr; 12(4):542-552. PubMed ID: 30653855
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emotional dysregulation in adult ADHD and response to atomoxetine.
    Reimherr FW; Marchant BK; Strong RE; Hedges DW; Adler L; Spencer TJ; West SA; Soni P
    Biol Psychiatry; 2005 Jul; 58(2):125-31. PubMed ID: 16038683
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Atomoxetine could improve intra-individual variability in drug-naïve adults with attention-deficit/hyperactivity disorder comparably with methylphenidate: A head-to-head randomized clinical trial.
    Ni HC; Hwang Gu SL; Lin HY; Lin YJ; Yang LK; Huang HC; Gau SS
    J Psychopharmacol; 2016 May; 30(5):459-67. PubMed ID: 26905919
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Adult attention deficit hyperactivity disorder (ADHD) with comorbid addictive disorder. Therapeutic challenges using the example of a survey of clinical practice].
    Adorjan K; Karch S; Martin G; Plörer D; Winter C; Hantschk I; Koller G; Erbas B; Pogarell O
    MMW Fortschr Med; 2019 Jul; 161(Suppl 5):7-12. PubMed ID: 31313269
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects of lisdexamfetamine dimesylate on emotional lability in children 6 to 12 years of age with ADHD in a double-blind placebo-controlled trial.
    Childress AC; Arnold V; Adeyi B; Dirks B; Babcock T; Scheckner B; Lasser R; Lopez FA
    J Atten Disord; 2014 Feb; 18(2):123-32. PubMed ID: 22740112
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-Term Pharmacotherapy of Adults With Attention Deficit Hyperactivity Disorder: A Literature Review and Clinical Study.
    Fredriksen M; Peleikis DE
    Basic Clin Pharmacol Toxicol; 2016 Jan; 118(1):23-31. PubMed ID: 26404187
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacological treatment for Attention Deficit Hyperactivity Disorder (ADHD) in children with comorbid tic disorders.
    Pringsheim T; Steeves T
    Cochrane Database Syst Rev; 2011 Apr; (4):CD007990. PubMed ID: 21491404
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined methylphenidate and atomoxetine pharmacotherapy in attention deficit hyperactivity disorder.
    Ozbaran B; Kose S; Yuzuguldu O; Atar B; Aydin C
    World J Biol Psychiatry; 2015; 16(8):619-24. PubMed ID: 26223958
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative benefits and harms of competing medications for adults with attention-deficit hyperactivity disorder: a systematic review and indirect comparison meta-analysis.
    Peterson K; McDonagh MS; Fu R
    Psychopharmacology (Berl); 2008 Mar; 197(1):1-11. PubMed ID: 18026719
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety of Treatments for ADHD in Adults: Pairwise and Network Meta-Analyses.
    Chierrito de Oliveira D; Guerrero de Sousa P; Borges Dos Reis C; Tonin FS; Maria Steimbach L; Virtuoso S; Fernandez-Llimos F; Pontarolo R; Cristina Conegero Sanches A
    J Atten Disord; 2019 Jan; 23(2):111-120. PubMed ID: 28366111
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship Between Treatment Duration and Efficacy of Pharmacological Treatment for ADHD: A Meta-Analysis and Meta-Regression of 87 Randomized Controlled Clinical Trials.
    Castells X; Ramon M; Cunill R; Olivé C; Serrano D
    J Atten Disord; 2021 Aug; 25(10):1352-1361. PubMed ID: 32075485
    [No Abstract]   [Full Text] [Related]  

  • 38. Relationships Between Functional Outcomes and Symptomatic Improvement in Atomoxetine-Treated Adult Patients with Attention-Deficit/Hyperactivity Disorder: Post Hoc Analysis of an Integrated Database.
    De Bruyckere K; Bushe C; Bartel C; Berggren L; Kan CC; Dittmann RW
    CNS Drugs; 2016 Jun; 30(6):541-58. PubMed ID: 27224994
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy, Acceptability, and Tolerability of Lisdexamfetamine, Mixed Amphetamine Salts, Methylphenidate, and Modafinil in the Treatment of Attention-Deficit Hyperactivity Disorder in Adults: A Systematic Review and Meta-analysis.
    Stuhec M; Lukić P; Locatelli I
    Ann Pharmacother; 2019 Feb; 53(2):121-133. PubMed ID: 30117329
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up.
    Su Y; Yang L; Stein MA; Cao Q; Wang Y
    J Child Adolesc Psychopharmacol; 2016 May; 26(4):362-71. PubMed ID: 26779845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.